Gliknik, a UM BioPark tenant, raises $4.9M

Gliknik Inc., a Baltimore biopharmaceuticals firm, has raised $4.9 million in a Series B round of financing.

Baxter Ventures led the funding round and was joined by existing investors, such as LifeTech Developments Fund.

Gliknik plans to use the financing to advance its Intravenous Immunoglobulin-mimetic lead compound, GL-2045. Gliknik will study the compound in autoimmune conditions, including Myasthenia gravis (a neuromuscular disorder.)

Gliknik, led by CEO David S. Block, is located in the…